Publications by authors named "D Kiefer"
Objective: In axSpA, validated PROs are well-established in clinical trials, but it remains unclear whether they comprehensively reflect patients' discomfort and disease status. We aimed to investigate how patients' self-reported disease status does compare to validated clinical trial measures during routine clinical visits.
Methods: Data from axSpA patients' initial and last five visits were retrospectively analyzed.
Context: Postoperative muscle weakness contributes to the development of aberrant gait biomechanics that persist following traditional anterior cruciate ligament reconstruction (ACLR). However, it is unknown if quadriceps weakness impedes the ability of ACLR patients to modify gait biomechanics using a real-time gait biofeedback (RTGBF) intervention.
Objective: The purpose was to determine if quadriceps strength associates with the ability to modify vertical ground reaction force (vGRF) during a RTGBF intervention.
Objectives: In axial spondyloarthritis (axSpA), early diagnosis is crucial, but diagnostic delay remains long and diagnostic criteria do not exist. We aimed to identify a diagnostic model that distinguishes patients with axSpA from patients without axSpA with chronic back pain based on clinical data in routine care.
Methods: Clinical data from patients with chronic back pain were used, with information on rheumatological examinations based on clinical indications.
Article Synopsis
- The text discusses a correction to a previously published article indexed under the DOI 10.3389/fgene.2022.987867.* -
- The correction aims to address specific inaccuracies or errors found in the original study.* -
- This update is important for maintaining the integrity of the research and ensuring accurate scientific communication.*
Article Synopsis
- The study aimed to evaluate the outcomes of switching patients with inflammatory rheumatic musculoskeletal diseases from the original adalimumab (ADA) to its biosimilar ABP501 over 6 months, focusing on comorbidity as a potential factor for stopping treatment.
- A total of 111 patients were analyzed, with 74.8% continuing ABP after 6 months, while some switched to other treatments or dropped out.
- The presence of comorbidities, particularly cardiovascular issues, was notable, but results indicated little difference in treatment continuation between patients with and without comorbidities, suggesting that both groups retained the biosimilar treatment similarly.